Navigation Links
Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Date:3/20/2017

Avexegen Therapeutics Inc., an innovative biotechnology company developing novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) for Neuregulin-4 (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis.

“With this licensing deal, Avexegen will continue to advance on its strategy to develop therapies for high unmet need GI disorders,” said Artin Asadourian, CEO of Avexegen Therapeutics.

Mark Frey, PhD, a principal investigator at The Saban Research Institute of CHLA, has demonstrated NRG-4 therapeutic proof of concept in preclinical models of NEC and inflammatory bowel disease. NRG-4’s efficacy is mediated by dual mechanisms that promote mucosal healing: the direct protection of the intestinal barrier and the suppression of inflammatory cytokines via its novel immunomodulatory action.

Currently, there are no FDA approved drugs for the treatment or prevention of Necrotizing Enterocolitis (NEC), which is a life-threatening disease that afflicts very low birth weight premature infants. NRG-4 has the potential to be the first such therapy for NEC.

About Avexegen Therapeutics, Inc.
Avexegen, founded in December 2014, is an emerging privately held biotech company based in San Diego, CA focused on developing novel treatments for a broad spectrum of inflammatory GI disorders. For more information please visit http://www.avexegen.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14155590.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
2. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
3. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
4. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
5. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
6. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
7. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
8. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
10. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
11. Capricor Therapeutics to Present at Two Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , ... May 22, 2017 , ... Stratevi, a boutique ... to the East Coast. It has opened an office in downtown Boston at 745 ... finding it increasingly more important to generate evidence on the value they provide, not ...
(Date:5/19/2017)... Shirley, New York (PRWEB) , ... May 19, 2017 , ... ... therapy techniques in treating gait disorders, Biodex Medical Systems, Inc. announces the release of ... time music therapy has been joined with a biomedical system to aid in rehabilitating ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... ... 17, 2017 , ... G-CON Manufacturing, Inc., the leader in ... Jornitz, was recognized as a Top 10 Industry Influencer on The Medicine Maker’s ... bettering the pharma industry and bringing life-changing medicines to market” across four categories. ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):